



NDA 21-130/S-037
NDA 21-131/S-030
NDA 21-132/S-035

SUPPLEMENT APPROVALS

Pharmacia & Upjohn Company
a subsidiary of Pfizer, Inc.
Attention: Nadia D. Kirzecky
Director, Pfizer Essential Health Global Regulatory Affairs Brands
235 East 42nd Street
New York, NY 10017

Dear Ms. Kirzecky:

Please refer to your Supplemental New Drug Applications (sNDAs) dated October 19, 2017, received October 19, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

- NDA 21-130/S-037: Zyvox (linezolid) Tablets, 400 mg and 600 mg
- NDA 21-131/S-030: Zyvox (linezolid) Injection, 2 mg/mL
- NDA 21-132/S-035: Zyvox (linezolid) Oral Suspension, 100 mg/5 mL

These Prior Approval supplemental new drug applications provide for updates to the **ADVERSE REACTIONS (6)** section, **Postmarketing Experience (6.2)** subsection, to add the adverse events of sideroblastic anemia and toxic epidermal necrolysis, along with minor editorial revisions.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended and they are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submissions, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copies should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Acting Deputy Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DMITRI IARIKOV
02/01/2018